Pipeline
Summary
Pipeline graphic of FID-007 drug candidate
Milestones
Head & Neck: Began Phase 2 enrollment in 2024
Ampullary or ICI Resistant: Go/no-go based on H&N study

Pipeline graphic of FID-022 drug candidate
Milestones
Begin Phase 1 enrollment in mid-2025

Pipeline graphic of ADC drug candidate